Skin ulceration potential of paclitaxel in a mouse skin model in vivo

Cancer

Volumn 78, Issue 1, 1996, Pages 152-156

  Dorr, Robert T ^a,b   Snead, Kristi ^a   Liddil, James D ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

antidotes; extravasation; paclitaxel infiltration; skin toxicity

Indexed keywords

ADJUVANT; ANTIDOTE; CREMOPHOR; DIMETHYL SULFOXIDE; HYALURONIDASE; HYDROCORTISONE SODIUM SUCCINATE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; EXTRAVASATION; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SKIN ULCER; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; PACLITAXEL; SKIN ULCER;

EID: 0030014695     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<152::AID-CNCR21>3.0.CO;2-Y     Document Type: Article

References (21)

1. Bicher A, Levenback C, Burke TW, Morris M, Warner D, DeJesus Y, et al. Infusion site soft-tissue injury after paclitaxel administration. Cancer 1995;76:116-20.
2. Parness J, Horowitz SB. Taxol binds to polymerized microtubules in vitro. J Cell Biol 1981;91:479-87.
3. Bryan J. Vinblastine and microtubules. II. Characterization of two protein subunits from the isolated crystals. J Mol Biol 1972;66:157-61.
4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5.
5. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
6. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
7. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85(5):384-8.
8. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5(8):1232-9.
9. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, Myles J, Mangioni C, van der Burg M, et al. Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1993;12:256.
10. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12(8):1621-9.
11. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263-8.
12. Ajani JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 1994;86(1):51-3.
13. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987;71(12):1171-7.
14. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50(4):219-43.
15. Dorr RT, Alberts DS, Chen H-SG. Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Methods 1980;4:237-50.
16. Dorr RT, Alberts DS, Stone A. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 1985;69(4):431-7.
17. Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985;74(1):113-20.
18. Dorr RT, Bool KL. Antidote studies of vinorelbine-induced skin ulceration in the mouse. Cancer Chemother Pharmacol 1995;36:290-2.
19. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93.
20. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr., et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10(9):1485-91.
21. Dorr RT, Alberts DS. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Invest New Drugs 1983;1:151-9.